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Purpose: To compare intravitreal triamcinolone acetonide (IVT) versus natural course in refractory diabetic 
macular edema.
Methods: In a prospective interventional case series, twenty five eyes with refractory DME which had been 
allocated to the sham group of a previous clinical trial underwent new examination and optical coherence 
tomography about 9 months after their first enrollment. Twenty eyes that met the inclusion criteria, visual 
acuity (VA) < 20/50 and central macular thickness (CMT) > 200 µm, were treated by 4 mg IVT. Evaluations 
were repeated at 2 and 4 months post-injection to imitate the similar examination intervals after sham 
injection. Corrected visual acuity and macular thickness changes following IVT were compared to the 
corresponding changes after sham injection (the natural course).
Results: Visual acuity changes within and between each period were not statistically significant. Visual 
acuity decreased 0.08 & 0.09 logMAR by 2 months and 0.06 & 0.04 logMAR by 4 months after sham and 
IVT injections, respectively. The changes of macular thickness after IVT and sham intervention were not 
meaningful either. However, the difference between thickness changes by 4 months (52±50 µm increase 
after sham vs. 262±115 μm reduction after IVT) was significant (P=0.014).
Conclusions: Concerning macular thickness, IVT has beneficial effect on refractory diabetic macular edema 
as opposed to observation. However, considering visual acuity, it does not induce significant difference in 
comparison to the natural course of the disease.
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Macular edema is the most important manifestation of 
non-proliferative diabetic retinopathy and a predominant 
cause of legal blindness in diabetic patients. According to the 
early treatment of diabetic retinopathy study (ETDRS), the 
treatment of choice for clinically significant macular edema 
(CSME) is laser therapy. However, some cases of CSME are 
refractory to laser therapy and do not have a good prognosis 
with such treatment.
1
Recently, some promising results have been shown in 
different studies for the treatment of refractory diabetic 
macular edema with intravitreal triamcinolone acetonide 
(IVT).
2-4 Since diabetic macular edema is a chronic disease 
and the effect of IVT has been shown to be transient,
5,6 the 
comparison of this therapeutic effect with the natural course 
of this ailment is necessary. In addition, there are a lot of 
systemic and ocular factors which influence the natural 
course and the therapeutic response in these patients.
6-9 
Therefore, controlling of such confounding elements in 
research programs seems to be essential.
In clinical trials, there is always a possibility of unequal 
distribution of various characteristics into the allocated 
groups and adjusting these many factors is rather difficult. 
Therefore, a study with two types of intervention on one 
individual group of cases would be able to overcome this 
problem. We performed a study by IVT injection on patients 
with refractory diabetic macular edema who had already been 
observed for a period of time without any treatment. The 
purpose was to compare the result of IVT treatment with the 
natural course of diabetic macular edema in one particular 
group of patients.
Materials and Methods
In this prospective interventional case series study, all of 
the patients in the control group of a previous clinical trial 
who had received sham injection (0.1 cc lidocaine 2% Kor J Ophthalmol Vol.21, No.2, 2007
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Fig. 1. Mean visual acuity before, 2, 4 and about 8 months 
after the sham injection.
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Fig. 2. Mean central macular thickness before, 2, 4 and about 
8 months after the sham injection.
subconjunctively) for refractory diabetic macular edema were 
recalled for examination and reassessment of macular 
thickness by optical coherence tomography (OCT-2, Zeiss, 
Dublin, CA) about 9 months after the first presentation. An 
informed consent was obtained from each patient. Both the 
primary trial and this part of the study were approved by the 
Review Board/Ethics Committee of the Ophthalmic Research 
Centre. The results of the primary trial have not been 
published yet.
The previous study included eyes meeting criteria for 
CSME based on the ETDRS definition, with an anticipated 
unfavorable visual outcome after initial or supplemental 
macular photocoagulation due to one or more of the 
following findings: 1- macular ischemia, 2- diffuse macular 
edema, 3- severe hard exudates (HE) accumulation in the 
fovea, and 4- lack of response to previous laser 
photocoagulations with the last one being more than 3 
months before. The patients were randomly assigned to the 
treatment (4 mg IVT) and the placebo groups. This primary 
trial demonstrated a transient improving effect in terms of 
visual acuity (VA) and central macular thickness (CMT) in 
IVT-received eyes versus the placebo-received cases. (Article 
in press)
In the current study, all of the placebo-received patients in 
the initial part were recalled for a new clinical and 
tomographic evaluation. IVT injection was planned for all 
patients except for those who met the following criteria: (1) 
intraocular surgery after the first intervention; (2) best 
corrected VA≥20/50; (3) intraocular pressure (IOP) > 21 
mmHg and/or taking anti-glaucoma medication at the time of 
re-examination; (4) lens opacity severe enough to interfere 
with VA testing and performing OCT; (5) CMT less than 200 
µm measured by OCT; (6) being candidate for intraocular 
surgery; (7) one-eyed patients; and (8) non-compliance.
Injections were done under sterile conditions in the 
operating room with topical anesthesia and insertion of a lid 
speculum. Four milligrams (0.1 cc) triamcinolone acetonide 
(Kenacort) was injected intravitrealy with a 27-gauge needle 
through the superotemporal quadrant. IOP was checked about 
10 minutes after injection with a Goldman applanation 
tonometer and anterior chamber paracentesis was performed 
if IOP exceeded 30 mmHg.
Examinations were performed at 2 and 4 weeks after 
injection to monitor IOP and the probable complications. In 
eyes with IOP>21 mmHg, timolol was prescribed twice daily 
and in refractory cases, one drop of dorzolamide three times 
a day was added.
Complete ophthalmic examination and OCT were repeated 
2 and 4 months after IVT injection in an attempt to replicate 
the follow-up periods after the primary injections in the first 
part of the study. The data collected from both the new 
exams and the evaluations after IVT injection (2nd 
intervention) were recorded to compare with the results 
following sham injection (1st intervention).
Ophthalmic examinations, both in the previous trial and in 
the current study, were carried out by two ophthalmologists 
who were not masked for the treatment received by the 
patients. However, best corrected VA measurements and 
OCT were performed by optometrists who were not aware 
of the protocols of the two studies. Best corrected VA 
measurements were based on the Snellen chart and were 
converted to the logarithm of the minimum angle of 
resolution (logMAR) scale for statistical evaluations.
Statistical analysis: It was performed using paired t and 
independent sample t tests for evaluating quantitative 
variables changes within and between the two interventions 
respectively. P values<0.05 were considered statistically 
significant.
Results
The results are presented in two parts: first, the long-term 
follow up results comparing the findings of the new exams 
with the previous data in all of the returned patients before 
the second intervention. Second, the results of IVT injection 
in which the findings after the two interventions (IVT vs. 
sham injection) were compared to each other only in cases 
who met the criteria for IVT administration.A Ramezani et al. DIABETIC MACULA BEFORE AND AFTER TRIAMCINOLONE
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Month
Sham period IVT period
P value between periods VA changes 
(logMAR)
P value
within period
VA changes 
(logMAR)
P value
within period
0 to 2 +0.08±0.06 0.186 +0.09±0.05 0.328 0.996
2 to 4 -0.02±0.06 0.717 -0.05±0.08 0.930 0.784
0 to 4 +0.06±0.07 0.357 +0.04±0.09 0.193 0.808
+ & - Signs imply increase and decrease in logMAR notation that means decrease and increase in VA, respectively.
Table 1. Visual acuity (VA) changes following IVT vs. sham injections in a particular group of cases with diabetic 
macular edema (paired t and independent samples t tests for changes within and between periods, respectively)
Month
Sham period IVT period
P value between periods CMT changes
 (µm)
P value
within period
CMT changes
 (µm)
P value
within period
0 to 2 +19±62 0.763 -131±70 0.088 0.119
2 to 4 -13±43 0.763 -17±74 0.834 0.968
0 to 4 +52±50 0.313 -262±115 0.107 0.014
+ & - Signs imply increase and decrease in CMT, respectively.
Table 2. Central macular thickness (CMT) changes following IVT vs. sham injection in a particular group of 
cases with diabetic macular edema (paired t and independent samples t tests for changes within and between 
periods, respectively)
Long-term follow up results: Twenty five cases (16 male, 
9 female) of the patients who were in the sham group of the 
preceding study returned for re-evaluation. The mean time 
interval between the sham injection and the new examination 
was 8.9±3.1 months (range: 4 to 15 months).
The comparison of VA changes between the new exam 
and each previous one (at months 0, 2, and 4 after the sham 
injection) were not statistically significant which implied on 
a stable VA in about 9 months of follow up without any 
treatment (Fig. 1).
The assessment of CMT between the prior phases and the 
time of recall are presented in Fig. 2. Although there was a 
mild increase in mean CMT during the follow up, paired t 
test did not show statistically significant changes between any 
of the compared times.
Results of IVT injection: Five of 25 returning cases were 
not candidates for IVT injection for the following reasons: 
VA≥20/50, vitreous hemorrhage, CMT<200 µm (two cases), 
and non-compliance. Therefore, 20 patients (11 male, 9 
female) with the mean age of 62±9 years were treated by 
IVT. The injections were carried out without any immediate 
complication except the entrance of drug particles into the 
anterior chamber in one case due to injection-induced IOP 
rise.
The comparison of VA changes between and within the 
two interventions (IVT and sham injection) did not show 
statistically significant difference (Table 1).
Until 4 months, there was a reduction (-127 µm) in mean 
CMT subsequent to IVT injection compared to a mild 
increase (+40 µm) after receiving sham intervention (Fig. 3); 
however, these differences within each intervention were not 
statistically significant (paired t test). Comparisons of thickness 
changes between the two interventions (independent sample 
t test) did not show significant difference either (P=0.119 for 
month 0 to 2, and P=0.968 for month 2 to 4), except in one 
stage. As shown in Table 2, the difference of changes 
between months 0 and 4 was significant (P=0.014), which 
implied on CMT reduction after IVT treatment in eyes which 
had been followed without any treatment for 9 months.
Paired t-test showed that IOP rise after receiving IVT was 
significant at months 2 and 4 (Fig. 4). Although mean IOP 
before IVT injection was 1.25 mmHg higher than it was 
before the sham treatment, the comparison of IOP changes 
following the two interventions demonstrated a significant 
increase of pressure with triamcinolone especially by 2 
months (Table 3).
Discussion
According to the results, VA and CMT in the patients with 
refractory diabetic macular edema did not undergo significant 
changes during 9 months of follow up. IVT treatment in such 
eyes reduced CMT by 4 months; however, its therapeutic 
effect on VA was not significant.
We could not detect any statistically significant VA 
improving effect after IVT injection, neither by 
before-and-after comparison nor in relation to the changes 
following sham injection. Jonas et al. showed that in 68% of 
IVT-received eyes VA improved for 2 Snellen lines; 
however, in control eyes the VA remained unchanged for 4 
months and then it decreased until the end of the follow up. 
The difference of VA changes between the two groups in 
their study was significant.
10 Note that the dosage of IVT in 
that study (25 mg) was higher than that of ours, and their 
control group underwent focal or grid macular laser therapy 
which indeed could have effects on the result.Kor J Ophthalmol Vol.21, No.2, 2007
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Fig. 3. Mean central macular thickness changes after sham and
IVT injections.
Month
Sham period IVT period
P value between periods IOP changes 
(mmHg)
P value    
within period
IOP changes
(mmHg)
P value
within period
0 to 2 +0.60±0.6 0.312 +4.06±1.3 0.008 0.014
2 to 4 -0.65±0.8 0.446 -1.25±1.7 0.477 0.725
0 to 4 -0.05±1.1 0.963 +2.83±1.0 0.014 0.076
+ & - Signs imply increase and decrease in IOP, respectively.
Table 3. Intraocular pressure (IOP) changes following IVT vs. sham injection in a particular group of cases with
diabetic macular edema (paired t and independent samples t tests for changes within and between periods, 
respectively)
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Fig. 4. Mean intraocular pressure changes after sham and IVT
injections.
Parolini demonstrated a transient VA improvement during 
3 months after IVT treatment which was followed by a 
deterioration of VA until 1 year.
9 Considering the effect of 
IVT on VA in refractory diabetic macular edema, different 
authors have mentioned different results. For instance, 
significant increase of VA by 6 months was reported in one 
study;
11 in another, the authors did not find any considerable 
difference between control and case groups with 24 months 
of follow up.
8
Comparison of CMT changes following IVT injection with 
its natural course in the present study demonstrated the 
improving effect of this treatment on macular edema by 4 
months. We did not perform OCT after 4 months; however, 
most of the similar studies with longer follow ups showed 
that the effect of IVT on macular thickness was transient.
6-9 
In a study on Chinese patients with diabetic macular edema, 
4 mg IVT reduced CMT significantly from 552±179 µm to 
326±145 µm and 427±145 µm at months 3 and 6 
respectively.
6 In Krepler's study with 9 months of follow up, 
thickness reduction (from 450±190 to 305±153 µm) was 
significant only at month one.
7
It is well known that IVT increases IOP which in most 
cases can be controlled by anti-glaucoma drugs. In a study 
by Jonas on 272 patients with different diseases treated by 
20 mg IVT, IOP more than 21, 30, 35, and 40 mmHg 
occurred in 112 (41.2%), 31 (11.4%), 15 (5.5%), and 5 
(1.8%) respectively. These IOP rises were treated by 
medication in all except 3 cases.
12 Although this complication 
is treatable, it may persist beyond the therapeutic effect of 
the drug. IOP elevation lasted for 8 months in the studies 
conducted by Jonas
12 and Martidis.
4
As we found from literature review, no study had been 
conducted to compare the effect of IVT on refractory diabetic 
macular edema with its natural course in one particular group 
of patients. The chronic nature of diabetic macular edema 
gave the opportunity for planning such a research. Since 
multiple and different ocular and systemic factors could affect 
the course of this disease and its response to any treatment 
modality, the present study with two kinds of managements 
on one group of cases probably had the power to ameliorate 
the influences of these confounding elements. However, there 
could have been some changes in the patient's systemic status 
between the times of two interventions that we were not 
aware of them. This fact along with rather small sample size 
can be regarded as limitations of this study.
In summary, this study like many others implied on the 
beneficial effect of IVT on diabetic macular edema. 
However, this effect was evident on macular thickness rather 
than on VA. Such discrepancy in responses of variables was 
seen also in Larsson's study.
13 Considering the stable nature 
of VA and macular thickness in patients with refractory 
diabetic macular edema, and the insignificant effect of IVT A Ramezani et al. DIABETIC MACULA BEFORE AND AFTER TRIAMCINOLONE
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on VA, we would not recommend IVT as a routine treatment 
modality for such cases.
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